SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
IMRA
--
0.00%
--
Imara Reports IMR-687 Granted Fast Track Designation, Rare Pediatric Disease Designation For Bet-Thalassemia
Benzinga · 3d ago
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 4d ago
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, toda
GlobeNewswire · 4d ago
Citigroup Downgrades Imara to Neutral, Raises Price Target to $34
Citigroup downgrades Imara (NASDAQ:IMRA) from Buy to Neutral and raises the price target from $30 to $34.
Benzinga · 06/30 11:51
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
GlobeNewswire · 06/29 21:01
Imara Added To Membership Of US Small-Cap Russell 2000 Index
Benzinga · 06/29 20:03
Biotech IPOs are booming -- but it's not all about Covid-19
CNN.com · 06/25 12:43
Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
GlobeNewswire · 06/25 12:00
Imara Receives Orphan Drug Designation For IMR-687 For Treatment Of Beta-thalassemia
BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare
Benzinga · 06/24 11:09
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the U.S. Food and Drug Administra
GlobeNewswire · 06/24 11:00
Here is What Hedge Funds Think About IMARA Inc. (IMRA)
Insider Monkey · 06/22 18:57
Microcaps mostly among midday movers
Seeking Alpha - Article · 06/15 16:31
Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation
Simply Wall St. · 06/13 13:44
Imara under pressure on underwhelming data in IMR-687 in sickle cell disease
Seeking Alpha - Article · 06/12 13:58
SVB Leerink Maintains Outperform on Imara, Raises Price Target to $64
SVB Leerink analyst Joseph Schwartz maintains Imara (NASDAQ:IMRA) with a Outperform and raises the price target from $27 to $64.
Benzinga · 06/12 13:44
Imara reports promising data from mid-stage trial for sickle cell treatment
MarketWatch · 06/12 12:46
Imara Highlights Presentation Of Interim Results From Phase 2a Study Of IMR-687 In Sickle Cell Disease At European Hematology Association Meeting
Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today
Benzinga · 06/12 11:01
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today presented interim results from its ongoing Phase
GlobeNewswire · 06/12 11:00
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Benzinga · 06/07 17:43